Acetylsalicylic Acid + clopidogrel — Competitive Intelligence Brief

Acetylsalicylic Acid + clopidogrel (Acetylsalicylic Acid + clopidogrel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual antiplatelet agent. Area: Cardiovascular.

marketed Dual antiplatelet agent Cyclooxygenase-1 (COX-1) and P2Y12 receptor Cardiovascular Small molecule

Target snapshot

Acetylsalicylic Acid + clopidogrel (Acetylsalicylic Acid + clopidogrel) — Hospital Universitari Vall d'Hebron Research Institute. This combination inhibits platelet aggregation through two complementary pathways: acetylsalicylic acid irreversibly inhibits cyclooxygenase to block thromboxane A2 production, while clopidogrel blocks the P2Y12 adenosine diphosphate receptor.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Acetylsalicylic Acid + clopidogrel TARGET	Acetylsalicylic Acid + clopidogrel	Hospital Universitari Vall d'Hebron Research Institute	marketed	Dual antiplatelet agent	Cyclooxygenase-1 (COX-1) and P2Y12 receptor
Clopidogrel+Aspirin	Clopidogrel+Aspirin	Seoul National University Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin)
Aspirin and clopidogrel/Ticagrelor	Aspirin and clopidogrel/Ticagrelor	Beijing Neurosurgical Institute	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel/ticagrelor)
Clopidogrel with aspirin	Clopidogrel with aspirin	University of Florida	marketed	Dual antiplatelet agent	P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin)
clopidogrel napadisilate + aspirin	clopidogrel napadisilate + aspirin	Seoul National University Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin)
ticagrelor + ASA	ticagrelor + ASA	Peking University Third Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)
clopidogrel bisulfate + aspirin	clopidogrel bisulfate + aspirin	Seoul National University Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual antiplatelet agent class)

1. Seoul National University Hospital · 3 drugs in this class
2. Chinese Academy of Medical Sciences, Fuwai Hospital · 1 drug in this class
3. Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
4. Inova Health Care Services · 1 drug in this class
5. Peking University Third Hospital · 1 drug in this class
6. Rigshospitalet, Denmark · 1 drug in this class
7. Texas Cardiac Arrhythmia Research Foundation · 1 drug in this class
8. The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 1 drug in this class
9. The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
10. University of Athens · 1 drug in this class